Daniel W. Rea

Daniel W. Rea

Dudley Road
Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 117 publications

UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.

UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.

Journal: Histopathology

Published: July 18, 2026

Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.

Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer.

Journal: NPJ breast cancer

Published: July 03, 2025

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Journal: NPJ breast cancer

Published: June 30, 2025

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Journal: British journal of haematology

Published: September 05, 2024

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Journal: Breast (Edinburgh, Scotland)

Published: August 25, 2024

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: The Lancet. Rheumatology

Published: November 16, 2023

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 11, 2023

Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.

Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 24, 2023

Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.

Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study.

Journal: Trials

Published: April 20, 2023

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 15, 2022

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: November 15, 2022

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.

Journal: Breast cancer research : BCR

Published: August 24, 2022

Showing 1-12 of 117

Last Updated: 09/26/2026